Non-small cell lung cancer

News

AZ, Daiichi eye December verdict for TROP2 ADC

The FDA has started a review of AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan as a therapy for lung cancer, the second drug in their antibody-drug conjugate (ADC

News

Tagrisso-chemo cleared in US as 1st-line lung cancer therapy

AstraZeneca’s Tagrisso can be used alongside chemotherapy as a frontline therapy for EGFR-positive non-small cell lung cancer (NSCLC), according to the FDA, consolidating

News

Sanofi drops lung cancer ADC tusamitamab ravtansine

French drugmaker Sanofi has halted the development of its antibody-drug conjugate (ADC) tusamitamab ravtansine after the drug failed a phase 3 trial in non-small cell lung

News

BMS bolts on SystImmune bispecific ADC in $8.4bn deal

The litany of big-ticket deals involving antibody-drug conjugates shows no sign of ending.

News

MSD, Moderna take mRNA jab into phase 3 for lung cancer

MSD and partner Moderna have started a late-stage trial of their personalised cancer vaccine V940 as a combination with MSD’s PD-1 inhibitor Keytruda for patients with non

R&D

Biofidelity’s ASPYRE: The future is bright for oncology

Genomic technology company Biofidelity has announced the launch of ASPYRE-Lung reagents (RUO) for research use, marking its second product launch this year, with the aim of providing simple

AZ, Daiichi eye December verdict for TROP2 ADC

Tagrisso-chemo cleared in US as 1st-line lung cancer therapy

Sanofi drops lung cancer ADC tusamitamab ravtansine

BMS bolts on SystImmune bispecific ADC in $8.4bn deal

MSD, Moderna take mRNA jab into phase 3 for lung cancer

Biofidelity’s ASPYRE: The future is bright for oncology

UK backs start-up Potential Sciences' AI-powered drug hunt

Discover a new era of healthcare panel engagement: Grounded ...

Non-small cell lung cancer

Editor's Picks